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Abstract
Background: Antioxidant supplementations have the potential to alleviate the atherosclerotic damage caused by 
excessive production of reactive oxygen species (ROS). The present study evaluated the effects of prolonged 
antioxidant treatment on arterial elasticity, inflammatory and metabolic measures in patients with multiple 
cardiovascular risk factors.
Methods: Study participants were randomly assigned to two groups. Group 1 received oral supplementation with 2 
capsules per day of Mid Life Guard, SupHerb, Israel. In each capsule vitamin C (500 mg) vitamin E (200 iu), co-enzyme 
Q10 (60 mg) and selenium (100 mcg), Group 2 received matching placebo(SupHerb) for 6 months.   Patients were 
evaluated for lipid profile, HbA1C, insulin, C-peptide, hs-CRP, endothelin, aldosterone, plasma renin activity and 
Homeostasis model assessment-insulin resistance (HOMA-IR). Arterial elasticity was evaluated using pulse wave 
contour analysis (HDI CR 2000, Eagan, Minnesota).
Results: Antioxidant-treated patients exhibited significant increases in large arterial elasticity index (LAEI) as well as 
small arterial elasticity index (SAEI). A significant decline HbA1C and a significant increase in HDL-cholesterol were also 
observed. In the placebo group, significant changes in LAEI, SAEI or metabolic measures were not observed.
Conclusions: Antioxidant supplementation significantly increased large and small artery elasticity in patients with 
multiple cardiovascular risk factors. This beneficial vascular effect was associated with an improvement in glucose and 
lipid metabolism as well as decrease in blood pressure.
Background
Oxidative stress has been considered as a potential patho-
genic mechanism for initiation and progression of athero-
sclerotic disease [1]. Excessive production of reactive
oxygen species, a mediator of the oxidative stress cascade,
leads to release of inflammatory cytokines, oxidation of
LDL and prothrombotic state, and finally results in
endothelial dysfunction and atherosclerotic vascular
lesions [2-4]. Adequate dietary, enzymatic and nonenzy-
matic antioxidant supplementation may be effective in
lowering oxidative stress. Although most trials with anti-
oxidants in experimental models of atherosclerosis have
demonstrated that this treatment is able to retard the
progression of atherosclerosis, the results of clinical trials
are equivocal [5]. Differences in the definition criteria of
patients who are potential candidates for antioxidant
treatment, type and dosage of antioxidant supplementa-
tion, as well as outcome measures may explain this vari-
ability. Since oxidative stress is activated by many
cardiovascular risks factors such as hypertension, hyperg-
lycemia, dyslipidemia and smoking, patients with multi-
ple cardiovascular risk factors could obtain beneficial
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effect from antioxidant treatment [6-9]. Additionally,
combinations of dietary antioxidants (vitamin C and vita-
min E) with carrier in mitochondrial oxidative phospho-
rylation (coenzyme Q10) and trace elements essential for
adequate function of many antioxidant enzymes (sele-
nium) may underlie the synergism between them and
amplify the positive antioxidant effect. The present study
was designed to determine the effect of antioxidant sup-
plementation with vitamin C, vitamin E, coenzyme Q10
and selenium on arterial compliance, inflammatory and
metabolic parameters in patients with multiple cardio-
vascular risk factors.
Methods
In a randomized, placebo-controlled study 70 patients
with at least two cardiovascular risk factors were
recruited from the hypertension outpatient clinic at
E.Wolfson Medical Center for study participation.
Screening procedures included physical examination,
complete blood chemistry; complete blood count, urinal-
ysis and electrocardiogram.
Cardiovascular risk factors were defined using the
National Cholesterol Education Program risk factors cat-
egories: hypertension (systolic blood pressure > = 140
mm Hg and/or diastolic BP > = 90 mm Hg and/or taking
antihypertensive medication); diabetes (fasting plasma
glucose level > = 126 mg/dl on at least two blood samples
and/or taking glucose lowering agents, hypertriglyceri-
demia (> = 1.7 mmol/l); low HDL cholesterol level (< 1.03
mmol/l in men and < 1.3 mmol/l in women); or current
cigarette smoking.
Patients with a history of unstable angina, MI, CVA or
major surgery within the six months preceding entrance
to the study were excluded. Patients with unbalanced
endocrine disease or any disease that might affect
absorption of medications were excluded, as were
patients with plasma creatinine > 2 mg/dl, elevation of
liver enzymes to more that twice the upper normal limit,
and electrolyte abnormalities. Patients included in the
study were stabilized on their previous medical treatment
in the outpatient clinic for up to three months, and an
effort was made not to change treatment during the
study. All concomitant medications were kept stable to
prevent possible effects on the study parameters.
The study was approved by the Institutional Review
Board and the patients signed a full informed consent.
S t u d y  p a r t i c i p a n t s  w e r e  r a n d o m l y  a s s i g n e d  t o  t w o
groups. Group 1 received oral supplementation with 2
capsules per day of Mid Life Guard, SupHerb, Israel. In
each capsule vitamin C (500 mg) vitamin E (200 iu), co-
enzyme Q10 (60 mg) and selenium (100 mcg), Group 2
received matching placebo(SupHerb) for 6 months.
Biochemical parameters
Blood sampling for full chemistry and metabolic parame-
ters, including fasting glucose, lipid profile, HbA1C, hs-
CRP, homocysteine, endothelin, aldosterone, plasma
renin activity was performed at baseline and at the end of
the study.
Arterial Elasticity Measurements
Arterial compliance measures were performed after an
overnight fast and before blood sampling. Measures were
performed between 8 and 10 AM, in a quiet, temperature
-controlled laboratory. With the subject in a supine posi-
tion, radial arterial waveforms were recorded for 30 sec.
The pressure transducer amplifier system was connected
to a specially designed device (Model CR-2000, Hyper-
tension Diagnostics Inc. Eagan, MN). The passive tran-
sient response of the arterial vasculature to the initial
loading conditions was determined by analyzing the dia-
stolic portion of the pressure pulse-wave form. This tech-
nique, which has been validated for its reproducibility
and used extensively [10-12], was performed with a sim-
ple noninvasive radial pulse wave recording and com-
puter analysis of the diastolic decay. This provides
separate assessment of the large artery or capacitive com-
pliance (C1) and small artery reflective or oscillatory
compliance (C2). Cardiac output and stroke volume were
computed from the average waveforms. Systemic vascu-
lar resistance (SVR) is calculated as mean arterial pres-
sure (MAP) divided by cardiac output (CO). Arterial
elasticity was determined at the baseline visit and at the
3- and 6 -month on-treatment visits.
Sample size
The primary endpoint in the present study was the paired
difference in small artery elasticity (SAEI) within each
group. With a sample size of n = 33 in each group, the
present study was designed to have not less than 80%
power to detect a true, within group difference of at least
1.2 ± 2 mL/mm Hg × 100 in SAEI in each of the two treat-
ment groups assuming a two-tailed alpha of 0.025 (pre-
serving to overall study alpha at 0.05).
Statistical analysis
Analysis of data was carried out using SPSS 10.0 statisti-
cal analysis software (SPSS Inc., Chicago, IL, USA, 1999).
For continuous variables, such arterial compliance
parameters and biochemistry data, descriptive statistics
were calculated and reported as mean ± standard devia-
tion. Normalcy of distribution of continuous variables
was assessed using the Kolmogorov-Smirnov test (cut off
at p = 0.01). Categorical variables such as sex and con-
comitant illnesses were described using frequency distri-
butions and are presented as frequency (%). The t-test for
independent samples was used to compare continuousShargorodsky et al. Nutrition & Metabolism 2010, 7:55
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variables by treatment group. Categorical variables were
compared by treatment group using the chi square test
(exact as needed). General linear modeling was used to
compare post-treatment continuous variables that dif-
fered by treatment group at baseline, including treatment
group as the fixed factor and the baseline value of the
modeled variable as a covariate. All tests are two-sided
and considered significant at p < 0.05.
Results
Demographic and clinical characteristics of the 70
patients with multiple cardiovascular risk factors are pre-
sented in Table 1. Group 1 included 36 patients who
received oral daily supplementation with vitamin C, vita-
min E, coenzyme Q10 and selenium. Group 2 included 34
patients who received placebo. As can be seen, both
groups were similar with respect to age, sex, BMI, pres-
ence of cardiovascular risk factors, baseline blood pres-
sure level and arterial elasticity parameters. Concomitant
medications were similarly distributed in both groups at
the start and end of the study.
Changes in hemodynamic and arterial elasticity 
parameters in patients treated with antioxidants
Table 2 shows six month follow-up of hemodynamic and
arterial elasticity parameters in patients received antioxi-
dants. Systolic blood pressure (SBP) decreased signifi-
cantly from 145.2 +/- 25.4 at baseline to 136.1 +/- 22.3
mmHg after 6 months of treatment (p < 0.001). Diastolic
blood pressure (DBP) decreased significantly during the
treatment period from 78.4 +/- 11.7 to 75.0 +/- 12.3
mmHg (p < 0.034). Heart rate did not change during the
study.
LAEI increased from 11.0 +/- 4.4 to 12.7 +/- 4.7 ml/mm
Hg × 100 after 6 months of treatment (p < 0.006) (Figure
1). SAEI increased significantly during the study from 3.3
+/- 1.9 to 4.7 +/- 2.7 ml/mm Hg × 100 (p < 0.0001) (Fig-
ure 2). Although SVR decreased by 11% during the treat-
ment period, this decrease did not reach statistical
significance (p = 0.102) (Table 2).
Changes in hemodynamic and arterial elasticity 
parameters in the control group
As shown in Table 2, systolic blood pressure as well as
diastolic blood pressure did not change significantly dur-
ing the study (p = 0.257 and p = 0.493, respectively).
Neither LAEI nor SAEI improved significantly during
the treatment period. LAEI was 12.9 +/- 6.2 ml/mmHg ×
100 at baseline and 11.3 +/- 4.3 ml/mmHg × 100 after 6
months of follow-up (p = 0.151) (Figure 1). SAEI was 3.6
+/- 1.5 at baseline and 3.7 +/- 1.9 ml/mmHg × 100 at the
end of the study (p = 0.732) (Figure 2). SVR tended to
increase during the study from 1594.7 +/- 351.3 to 1638.7
+/- 311.3 dyne × sec × cm, however this increase did not
reach statistical significance (p = 0.533) (Table 2).
Changes in metabolic and inflammatory parameters during 
6-month treatment period
As shown in Table 2, levels of HbA1C decreased signifi-
cantly from 7.08 ± 1.69% to 6.33 ± 2.3% (p = 0.022) in
patients received antioxidants. Additionally, significant
increase in HDL-cholesterol (p = 0.022) and marginal
declines in triglycerides (p = 0.058) as well as total choles-
terol levels (p = 0.074) were observed in antioxidant
treated patients.
Metabolic parameters including HbA1C, triglycerides,
total cholesterol, HDL-cholesterol and CRP did not
change in placebo group during the study.
Discussion
The present randomized, placebo controlled study dem-
onstrates that antioxidant supplementation with vitamin
C, vitamin E, coenzyme Q10 and selenium significantly
increased large and small artery elasticity in patients with
multiple cardiovascular risk factors. This beneficial vas-
cular effect was associated with an improvement in glu-
cose and lipid metabolism as well as significant decrease
in blood pressure.
Assessment of arterial function and structure can serve
as a surrogate endpoint for prediction of morbid events
and for estimation of success of treatment. Pulse wave
contour analysis using the modified Windkessel model is
one of several noninvasive methods for estimation of
arterial properties. Numerous studies performed with the
HDI CR-2000 equipment have shown good correlation to
age, cardiovascular risk factors and markers of disease
[13]. Therapeutic interventions with medications like sta-
tins, angiotensin II receptor blocking agents as well as
weight loss, have also shown improvement in LAEI and
SAEI which may suggest lowering of cardiovascular risk.
Nevertheless, no major prospective study associating
a r t e r i a l  e l a s t i c i t y  w i t h  c a r d i o v a s c u l a r  e v e n t s  h a s  b e e n
performed. Although PWA using the modified Windkes-
sel model has some limitations, this method provides
complementary information about vascular health.
The favorable vascular effect of antioxidants has been
observed in vitro and in animal models of atherosclerosis
[14-16]. However, data on long-term vascular impact of
antioxidant supplementation in humans are limited and
controversial. The findings of the present study concur
with those of previous study that has shown substantial
reduction in the progression of common carotid athero-
sclerosis during three year treatment with combined sup-
plementation of both vitamin E and vitamin C [17].
Additionally, the beneficial effect of antioxidant supple-
mentation on LDL oxidation and endothelial flow has
been demonstrated [18,19]. Moreover several prospective
randomized controlled clinical trials such as Cambridge
Heart Antioxidant Study, Secondary Prevention with
Antioxidants of Cardiovascular Disease in End-stageShargorodsky et al. Nutrition & Metabolism 2010, 7:55
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Table 1: Baseline demographic and clinical characteristics of study patient
Variables Patients received antioxidants Patients received placebo p value
n = 36 n = 34
Age (y) 62.17 ± 6.21 62.97 ± 5.09 0.559
Male/Female 21/13 15/21 0.678
BMI 30.10 ± 4.04 29.83 ± 5.06 0.968
Current smokers, n (%) 8 (23.53%) 10 (27.8%) 0.684
Hypertension, n (%) 25 (75.53%) 26 (72.2%) 0.902
Diabetes mellitus, n (%) 13 (38.23%) 9 (25%) 0.233
Dyslipidemia, n (%) 26 (76.47%) 28 (77.8%) 0.896
Obesity, n (%) 17 (50%) 14 (38.9%) 0.349
Family history of IHD, n (%) 26 (76.5%) 27 (75%) 0.886
Concomitant medication:
Statins (%) 25 (73.53%) 27 (75%) 0.888
ACEIs/ARBs (%) 19(55.88%) 12 (33.33%) 0.150
Diuretics (%) 6 (17.64%) 2 (5.56%) 0.112
B-blockers (%) 19 (55.89%) 16 (44.4%) 0.338
CCB-blockers (%) 10 (29.41%) 11 (30.56%) 0.917
Aspirin (%) 13 (38.23%) 16 (44.45%) 0.598
Baseline systolic BP (mm/Hg) 125.2 ± 25.4 138.0 ± 20.8 0.203
Baseline diastolic BP (mm/Hg) 78.4 ± 11.7 75.9 ± 7.8 0.291
Baseline fasting glucose (mg/dl) 127.1 ± 52.8 118.9 ± 42.2 0.476
Baseline HbA1C (%) 7.1 ± 1.7 6.8 ± 1.4 0.391
Baseline total cholesterol (mg/dl) 201.5 ± 53.1 198.8 ± 50.8 0.833
Baseline LDL Cholesterol (mg/dl) 117.5 ± 43.7 118.3 ± 47.1 0.945Shargorodsky et al. Nutrition & Metabolism 2010, 7:55
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Renal Disease study and Cholesterol Lowering Athero-
sclerosis Study reported that the administration of anti-
oxidants reduced the risk of cardiovascular disease [20-
22]. Nevertheless, subsequent large interventional studies
do not support a benefit from antioxidant supplementa-
tion [23,24]. These clinical trials have demonstrated that
vitamin E alone or in combination has no effect on the
risk of death or prevention of cardiovascular disease.
Moreover, a dose-response meta-analysis has shown that
high-dosage vitamin E supplementation was associated
with a small but statistically significant increased risk for
mortality [25]. The lack of benefit seen in these clinical
trials does not disprove the central role of oxidative stress
in atherosclerosis and justify investigating the overall
clinical impact of antioxidant treatment.
Although the anti-atherogenic effect of antioxidants
has been assessed in several experimental studies, the
mechanisms by which these agents inhibit atherosclerosis
remain to be clarified. Combined supplementation of
vitamin E and C have been shown to inhibit DNA oxida-
tion by H2O2 in human lymphocytes, to enhance endoge-
nous plasma and tissue antioxidant defenses and restore
endothelium-dependent vasoactivity [18,26,27]. Coen-
zyme Q10 which plays an essential role as an electron car-
rier in mitochondrial oxidative phosphorylation,
improves endothelial dysfunction in diabetic patients
[28]. Finally, selenium as a determinant of antioxidative
glutathione peroxidase 1 expression and activity, provides
significant protection of the coronary artery endothelium
against damage by oxidative stress [29].
The findings of the present study concur with those of
previous studies that have shown substantial reduction in
blood pressure and improvement in long-term glycaemic
control with oral CoQ supplementation, reduction in
plasma glucose and insulin resistance with high doses of
vitamin E supplementation and significant reduction in
blood pressure levels with vitamin E as well as vitamin C
in hypertensive patients [30-33]. Nevertheless, which
particular antioxidant or combination of antioxidants is
responsible for the favorable metabolic effect in the pres-
ent study remains uncertain. Additionally, we cannot
exclude the possibility that specific antioxidant combina-
tion which was used in the present study, has a contribu-
tory effect of on blood pressure, glucose and lipid
homeostasis as well as on improvement of vascular elas-
ticity.
In the present study, we did not observe significant
changes in humoral factors such as homocystein,
endothelin, aldosterone and renin in subjects received
antioxidant supplementation. Levels of urine cathe-
cholamines also did not change during the treatment
period. These findings emphasize a previously published
data which have shown that patophysiologic mechanism
of antioxidants action is independent of the changes in
plasma concentration of blood pressure modulators, such
as renin, aldosterone, endothelin [34], although the pre-
cise mechanism for antioxidant action on the vasculature
remains to be elucidated. Figure 1 LAEI by groups during 6-month follow-up.
Baseline HDL% 22.1 ± 4.6 26.0 ± 5.4 0.004
Baseline triglycerides (mg/dl) 189.5 ± 95.0 122.8 ± 56.5 0.001
Baseline hs-CRP (mg/dl) 1.84 ± 2.9 1.35 ± 1.6 0.616
Baseline endothelin(fmol/ml) 0.7 ± 2.6 1.4 ± 4.8 0.293
Baseline homocysteine (μmol/l) 9.2 ± 2.8 8.8 ± 3.1 0.486
Baseline renin (ng/ml/hr) 1.8 ± 3.4 1.5 ± 1.8 0.695
Baseline aldosteron (pg/ml) 7.4 ± 5.6 6.7 ± 4.5 0.590
Baseline urine cathacholamines (mg/
24 h)
24.74 ± 22.4 19.5 ± 12.1 0.278
Table 1: Baseline demographic and clinical characteristics of study patient (Continued)Shargorodsky et al. Nutrition & Metabolism 2010, 7:55
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Our study has several limitations. First, the present
study contains relatively small number of participants
and larger studies are required to establish the beneficial
vascular effect of antioxidant supplementation. Second,
we did not measure plasma levels of the antioxidants
which would have added the information regarding treat-
ment compliance and would have elucidated the
pathophysiology for vascular action of antioxidants. Fur-
thermore, since the present study has focused on patients
with multiple cardiovascular risk factors, the application
of our findings to other patient populations remains
uncertain.
Conclusion
We have demonstrated that combined antioxidant sup-
plementation with vitamin C, vitamin E, coenzyme Q10
and selenium has beneficial effect on glucose and lipid
metabolism, blood pressure and arterial compliance in
p a t i e n t s  w i t h  m u l t i p l e  c a r d i o v a s c u l a r  r i s k  f a c t o r s .  T h e
Table 2: Change from baseline in homodynamic, arterial stiffness and metabolic variables in each group
Variables Patients received antioxidants Patients received placebo
baseline 6 month p-value baseline 6 month p-value
Systolic BP (mm/Hg) 145.2 ± 25.4 136.1 ± 22.3 0.001 138.0 ± 20.8 135.0 ± 21.6 0.257
Diastolic BP (mm/Hg) 78.4 ± 11.7 75.0 ± 12.3 0.034 75.9 ± 7.8 75.0 ± 10.3 0.493
LAEI(ml/mm Hg × 10) 11.0 ± 4.4 12.7 ± 4.7 0.006 12.9 ± 6.2 11.3 ± 4.3 0.151
SAEI(ml/mm Hg × 100) 3.3 ± 1.9 4.7 ± 2.7 0.0001 3.6 ± 1.6 3.7 ± 1.9 0.732
SVR(dynes•sec/cm5) 1817.0 ± 751.5 1617.3 ± 305.2 0.102 1594.9 ± 351.3 1638.7 ± 311.3 0.533
Glucose(mg/dl) 127.0 ± 52 129 ± 62 0.535 118.9 ± 42 123.2 ± 55 0.496
HbA1C(%) 7.08 ± 1.69 6.33 ± 2.3 0.022 6.82 ± 1.44 6.86 ± 1.66 0.767
Total Cholesterol(mg/dl) 201.5 ± 53.1 180.7 ± 58.3 0.074 197.12 ± 50 186.80 ± 37.78 0.125
Triglycerides(mg/dl) 189 ± 94 170.4 ± 72 0.058 124.5 ± 56.5 127.83 ± 46.7 0.645
HDL% 22.1 ± 4 26.2 ± 10 0.022 26 ± 5.4 27.11 ± 5.5 0.212
LDL Cholesterol(mg/dl) 116.8 ± 44.4 103.4 ± 47 0.13 117.91 ± 47.9 109.0 ± 33.1 0.135
hs-CRP(mg/dl) 1.94 ± 3 0.62 ± 0.77 0.222 1.44 ± 1.59 0.95 ± 0.90 0.271
Renin (ng/ml/hr) 1.79 ± 3.4 2.27 ± 2.6 0.494 1.36 ± 1.55 1.91 ± 1.87 0.149
Aldosterone(pg/ml) 7.38 ± 5.6 8.2 ± 5.06 0.354 6.70 ± 4.5 7.00 ± 3.84 0.638
Homocysteine(μmol/l) 9.24 ± 2.82 9.19 ± 2.83 0.911 8.75 ± 3.04 9.11 ± 3.3 0.139
Ur cathacholamines(mg/24 h) 24.74 ± 21 28.5 ± 19 0.118 19.54 ± 12 22 ± 20 0.283Shargorodsky et al. Nutrition & Metabolism 2010, 7:55
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findings of the present study justify investigating the
overall clinical impact of antioxidant treatment in this
population.
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